Outcomes following the discontinuation of biologic therapy in patients with severe asthma
Allergology International · 2026
DOI: 10.1016/j.alit.2025.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2026. Verfasst von Tadao Nagasaki und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Nara, Japan. Hauptthemen laut MEDLINE: Asthma, Biological Therapy, Anti-Asthmatic Agents, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tottori University, Nagoya City University, Kyoto University.
Abstract (Originalsprache)
BACKGROUND: Biologic therapies are pivotal in managing severe asthma. Despite their efficacy, some patients discontinue biologics, with varying outcomes. Predictors of successful versus unsuccessful discontinuation remain poorly defined. This study aimed to identify clinical factors associated with post-discontinuation outcomes in a real-world practice. METHODS: This retrospective cohort included adults with severe asthma who had received biologics for at least 12 months and subsequently discontinued therapy for a minimum of three consecutive months. We assessed the effects of baseline blood eosinophilia (≥300 cells/μL), residual sputum symptoms during biologic therapy, treatment responsiveness, biologic class, and discontinuation reasons on post-discontinuation asthma exacerbation rates using multivariable Cox models. RESULTS: A total of 118 patients were analyzed. The Kaplan-Meier analysis estimated a 65 % exacerbation-free probability at 12 months after discontinuation. Factors associated with successful discontinuation included a robust clinical response and absence of exacerbations before cessation. Conversely, baseline eosinophilia, residual sputum symptoms during biologics, and discontinuation due to inadequate therapeutic response or financial burden were associated with post-discontinuation exacerbations. In class-stratified restricted models, persistent sputum remained significantly associated with post-discontinuation exacerbations after stopping anti-IL-5 therapies, while baseline eosinophilia was associated with post-discontinuation exacerbations after stopping anti-IgE or anti-IL-4Rα. Among patients with sputum symptoms or poor-response discontinuation, the overall frequency of exacerbations declined after discontinuation. CONCLUSIONS: Baseline eosinophilia, persistent sputum during therapy, and discontinuation prompted by poor response or cost may serve as risk factors for post-discontinuation exacerbations; however, risk is phenotype- and class-dependent. Careful patient selection and monitoring are essential when considering the discontinuation of biologic treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, Nara, Japan.
- Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: hmatsumoto@med.kindai.ac.jp.
- Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan; Osaka-fu Saiseikai Tondabayashi Medical Welfare Center, Tondabayashi, Japan.
- Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
- Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Japan.
Förderung
- Tottori University
- Nagoya City University
- Kyoto University
- Yamaguchi University
- Kinki University
- Keio University
- Nihon University
- Okayama University
Zitieren
APA
Nagasaki, T., Matsumoto, H., Iwanaga, T., Matsunaga, K., Sekiya, K., Harada, T., Sakurai, S., Harada, N., Koya, T., Fukunaga, K., Kaneko, T., Asai, K., Komase, Y., Gon, Y., Tanaka, A., Sagara, H., Sunadome, H., Nagano, T., Nakamura, Y., …, & Tohda, Y. (2026). Outcomes following the discontinuation of biologic therapy in patients with severe asthma. Allergology International. https://doi.org/10.1016/j.alit.2025.12.004
Vancouver
Nagasaki T, Matsumoto H, Iwanaga T, Matsunaga K, Sekiya K, Harada T, et al. Outcomes following the discontinuation of biologic therapy in patients with severe asthma. Allergology International. 2026. doi:10.1016/j.alit.2025.12.004
BibTeX
@article{Nagasaki2026,
author = {Nagasaki, Tadao and Matsumoto, Hisako and Iwanaga, Takashi and Matsunaga, Kazuto and Sekiya, Kiyoshi and Harada, Tomoya and Sakurai, Shogo and Harada, Norihiro and Koya, Toshiyuki and Fukunaga, Koichi and Kaneko, Takeshi and Asai, Kazuhisa and Komase, Yuko and Gon, Yasuhiro and Tanaka, Akihiko and Sagara, Hironori and Sunadome, Hironobu and Nagano, Tatsuya and Nakamura, Yoichi and Niimi, Akio and Hattori, Noboru and Hajiro, Takashi and Fujimoto, Hajime and Hojo, Masayuki and Miyahara, Nobuaki and Yamaguchi, Masafumi and Tsuji, Kimiko and Sano, Akiko and Haraguchi, Ryuta and Sano, Hiroyuki and Muraki, Masato and Tohda, Yuji},
title = {Outcomes following the discontinuation of biologic therapy in patients with severe asthma},
journal = {Allergology International},
year = {2026},
doi = {10.1016/j.alit.2025.12.004}
}
EUVIMED